Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Spanish Breast Cancer Research Group)"
Count: 47
Selected: 0
NCT IDTitle
NCT05063786Trial of Trastuzumab + ALpelisib +/- Fulvestrant vs Trastuzumab + Chemotherapy in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)
NCT00545077Bevacizumab + Endocrine Treatment vs Endocrine Treatment as First Line in Postmenopausal Women
NCT00130533Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients
NCT04379908Healthy Lifestyles and Quality of Life in Women With Breast Cancer
NCT03390894Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
NCT04603820Registry Study of Pregnancy and Breast Cancer
NCT04370522Characterization of Innate Immune System in Patients With Luminal Advanced Breast Cancer
NCT04293393Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients
NCT03860740Effect of Physical Exercise on Tumor Proliferation of Luminal B Breast Cancer Patients
NCT03847220Study of the Utility of the BOMET-QOL Questionnaire Patients With Breast Cancer and Bone Metastasis
NCT03829306Unraveling KAdcyla Resistance In Human Epidermal Growth Factor Receptor 2(HER2) Positive Advanced Breast Cancer (KATIA)
NCT03800355Study on the Progress of Breast Cancer Cases in Males and the Assessment of Relapse Risk
NCT03210974Retrospective Observational Study About Evolution of Patients With Breast Cancer in Hospitals From GEICAM Group
NCT03205761Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
NCT03025880Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
NCT02819882A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02690480Fulvestrant (F)+Placebo vs F+Palbociclib First Line for Postmenopausal Hormone Receptor+ Advanced Breast Cancer
NCT02028507Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
NCT02027376Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients
NCT01875367Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
NCT01733628Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Colorectal Cancer
NCT01598285A Combined GWAS and miRNA for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer
NCT01565499Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
NCT01377363Evaluation of Degree of Conversion of HER2 Receptor Between Primary Breast Cancer and Metastasis
NCT01306942Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
NCT01298193Incidence of Chemotherapy-Induced Nausea and Vomiting Associated With Docetaxel-Cyclophosphamide in Early Breast Cancer.
NCT00841828Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
NCT00543127Fulvestrant (Faslodex) + Anastrozole (Arimidex) vs Anastrozole
NCT00434941Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours
NCT00432172Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients
NCT00258960Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
NCT00130507Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With Trastuzumab
NCT00130494Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
NCT00129935EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
NCT00129922Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer
NCT00129896Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients
NCT00129389FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients
NCT00129376Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients
NCT00128856Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients
NCT00128843Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients
NCT00128778Maintenance Treatment With Liposomal Doxorubicin (Caelyx) in Metastatic Breast Cancer Patients
NCT00128310Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
NCT00128297Pamidronate Administration in Breast Cancer Patients With Bone Metastases
NCT00121992Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment
NCT02413008A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting
NCT04622319A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
NCT01899079A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay